Tag: BioVentures

Events

BioVentures participates in AUTM University Conference 2025 in New Orleans  

BioVentures participated in the AUTM University Conference 2025, held from October 26–29 in New Orleans. The event brought together professionals from technology transfer offices across the country to exchange knowledge, explore emerging trends, and strengthen collaboration within the tech transfer community.  The conference offered a valuable opportunity to learn from experts, exchange best practices, and strengthen collaboration across the national tech transfer network.  “From insightful sessions to meaningful networking moments, this experience was truly inspiring,” said Britney Bobo, Project Coordinator at BioVentures. “I had the chance to learn from industry experts, share ideas with peers, and dive deeper into the evolving world of tech transfer and innovation.”  By taking part in AUTM University, BioVentures reinforces its commitment to advancing technology commercialization and promoting innovation through collaboration and professional development. 

Read More »
Blog

BioVentures Receives Chancellor’s Circle Grant to Expand Student Innovation Training

BioVentures LLC has been awarded a $15,000 Chancellor’s Circle Grant to support the initiative “Empowering Student Innovation: Building an Innovation and Entrepreneurship Ecosystem at UAMS.” The program provides UAMS medical and STEM students with hands-on training in intellectual property, startup development, translational research, and commercialization. By integrating scientific research, technology transfer, and entrepreneurial education, it creates structured, experiential pathways for students and trainees to transform scientific ideas into innovations that improve the health and well-being of Arkansans. Megan Reed, Ph.D., MBA, senior licensing associate with BioVentures, accepted the grant on behalf of the organization. This initiative reflects BioVentures’ ongoing mission to bridge research and commercialization at UAMS and to empower the next generation of innovators working to translate discoveries into real-world health solutions.

Read More »
Events

UAMS Showcase of Medical Discoveries Highlights BioVentures-Supported Innovation 

The latest UAMS Showcase of Medical Discoveries, held on October 22 at the Jackson T. Stephens Spine & Neurosciences Institute, celebrated the spirit of innovation and entrepreneurship driving research at UAMS. The event featured projects supported by BioVentures LLC, UAMS’ technology transfer office and business incubator, underscoring how discoveries in the lab are evolving into real-world health solutions and startups across Arkansas.  Eric Peterson, Ph.D., President of BioVentures, opened the event by highlighting the courage it takes for researchers to move their discoveries toward commercialization, noting that “commercialization is a pathway to getting biomedical inventions to the bedside.”  Attendees explored a diverse range of innovations, from new cancer immunotherapies and diagnostic assays to medical devices, AI-driven imaging tools, and novel drug candidates. Projects included the Smart Tracheal Collar, a reusable monitoring device for pediatric patients with tracheostomies, and StaphGuard Biofilm, a first-in-class small molecule developed by VanGuard Biofilm LLC to prevent implant infections.  Daniel Voth, Ph.D., UAMS Vice Chancellor for Research & Innovation, emphasized the critical role of BioVentures in helping UAMS investigators protect intellectual property, form startups, and connect with industry partners and investors.  The event drew a strong crowd of faculty, researchers, and entrepreneurs, reflecting the growing momentum of commercialization efforts across the UAMS campus. Each project showcased the power of collaboration between science and business to advance healthcare and strengthen Arkansas’s biomedical economy.  A full gallery of photos from the event is available below. 

Read More »
Events

BioVentures to Join the UAMS Showcase of Medical Discoveries 

Join us on October 22, from 4–6 PM at the Jack Stephens Spine Institute (12th Floor) for the next UAMS Showcase of Medical Discoveries, focused on UAMS intellectual property and innovations.  The event will feature technologies developed by UAMS researchers and supported through BioVentures, offering a look at discoveries with the potential to improve health outcomes and drive commercialization.  Visit the official event page for more details.  

Read More »
Events

HSE Grand Rounds to Feature Dr. Stefanie Kennon-McGill

Stefanie Kennon-McGill, Ph.D., Senior Program Manager at BioVentures LLC, will be the featured speaker at 2 p.m. Wednesday, August 27, for the Health Sciences Entrepreneurship Grand Rounds. The topic will be “Leveraging Commercialization to Further Your Impact.” Join us at the Winthrop P. Rockefeller Cancer Institute, 10th Floor, Betsy Blass Conference Room.  The UAMS community and public are welcome to attend.

Read More »
Blog

From Disclosure to Market: How the BioVentures Process Works 

Curious how an idea becomes a protected invention at UAMS?  At BioVentures, we guide innovators through every step, from disclosure to patent decisions and market strategy. Here’s how the process works, what to expect, and how we support you along the way. 1) Submit Your Invention Disclosure  The first step is fully and adequately disclosing your invention to BioVentures by submitting an invention disclosure. Even if you’ve already reached out to schedule a meeting, we require a disclosure to initiate the process. It allows us to review the technology in advance, and gather essential information on compliance, funding, and inventorship.  We’ve recently adopted a new AI-powered disclosure platform to simplify the process. You can upload relevant documents—papers, figures, posters, presentations—and the system will generate a draft disclosure for you to review and edit before submission:  👉 Submit your disclosure  The form captures a complete overview of your invention, its potential applications, and any existing data or prototypes. Once submitted, BioVentures typically reviews the disclosure within 1–2 weeks before scheduling a meeting with you.  Typical timing: BioVentures review in 1–2 weeks.  2) Meeting with the Technology Manager  We meet with the inventor to clarify the technology, confirm federal compliance needs, capture inventor and funding information, and discuss long‑term goals and commercialization paths.  Typical timing: Scheduled within 1–2 weeks after disclosure review.  3) P&CC Decision (Patent & Copyright Committee)  The inventor presents at the P&CC. This committee reviews the presented technology and makes a determination on how the technology should be protected. Outcomes can include:  Typical timing: P&CC is usually scheduled 1–2 months after acceptance of the disclosure.  4) Protection Strategy Based on P&CC Outcome  The legal protection route follows the P&CC decision. If a provisional patent filing is recommended, we move quickly to secure a priority date and a 12‑month window to strengthen data and assess market potential. This is because in the United States is a first to file country which means that the right to a patent generally belongs to whichever inventor files an application with the USPTO first, not to whoever first conceives the idea. As such, protecting your invention in a timely manner is important to us.   Typical timing: Provisional filing is typically completed within a few weeks of the P&CC meeting.  5) Marketing and Commercial Pathways  If the inventor agrees, we begin targeted outreach. Options include:  Why Early Disclosure Matters  Submitting your invention disclosure early is essential. It helps preserve your patent rights before any public disclosure or publication, ensuring your ability to pursue protection. Early disclosure also allows BioVentures to align your IP strategy with funding sources and compliance requirements, and accelerates our ability to evaluate the market potential and identify relevant partners.  This overview is for general information and does not constitute legal advice. Specific strategies and timelines may vary by technology.  Have an invention to disclose? Submit your disclosure now!

Read More »
Blog

BioVentures Supports UAMS M1 Students in PCAR Summer Program

BioVentures supported University of Arkansas for Medical Sciences (UAMS) first-year medical students this summer through the Partnership in Cancer Research (PCAR) program. Over eight weeks, participants worked in multidisciplinary teams to address real-world challenges in cancer prevention, diagnosis, treatment, or survivorship. The program culminated in entrepreneurial pitch presentations to a panel of judges. Three BioVentures team members served as mentors, advising students on refining problem statements, assessing market opportunities, and developing business models. Another team member participated as a judge, providing feedback from a commercialization perspective. The collaboration aimed to foster entrepreneurial thinking, highlight the role of innovation in cancer care, and encourage future clinician-innovators at UAMS. This initiative reflects BioVentures’ ongoing commitment to advancing healthcare entrepreneurship and translating research into real-world impact.

Read More »
Blog

Building Translational Skills: Inside the 2025 BioVentures Internship 

BioVentures’ 2025 interns modernized core data systems and explored how UAMS innovations reach the market, bridging science and business.  BioVentures is wrapping up its 2025 Internship Program on August 1, with two standout students who have brought fresh energy and dedication to the office: Carter Horton and Nyera Ali.   Carter, a sophomore in Biomedical Engineering and National Merit Scholar at the University of Arkansas, described his experience by saying: “This internship has shown me how science and business connect to improve lives. It’s exciting to see it firsthand.”  Nyera, a rising senior at Pulaski Academy, is a Model United Nations standout and one of only seven students from Arkansas selected to compete at the prestigious Regeneron International Science and Engineering Fair for her genome-editing research. Participating through the Summer Research Institute (SRI), she has been working with Dr. Mitch McGill on research involving acetaminophen-induced liver injury.   Throughout the summer, both interns have played a role in transferring and organizing key data into a new system, a project that will serve as the foundation for future operations at BioVentures. In doing so, they’ve gained direct exposure to the process of technology transfer and learned how discoveries at UAMS move from the lab into the real world through commercialization.  We’re grateful to have had them with us this summer and look forward to seeing where their paths lead next.  Interested in interning with BioVentures in 2026? Contact tforcum@uams.edu. 

Read More »
News

Amy Hopper Swan Joins BioVentures as Strategy Consultant

Amy Hopper Swan is the founder of Swan Impact Strategies, a consulting firm that helps mission-driven organizations design and deliver high-impact programs. With nearly a decade of experience in entrepreneurship, program management and strategic planning, Amy has supported statewide and national initiatives to expand innovation, secure funding and measure outcomes.  Amy will help research and communicate BioVentures’ impact while supporting strategic planning and the exploration of diverse funding models to support entrepreneurship at UAMS, ACH and CAVHS.  She brings a strong background in economic development, impact storytelling and startup support, with a particular focus on translating research into real-world solutions.  Meet Amy at Innovation Week.

Read More »